Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

A research team has identified the transcription factor Lhx2 (LIM homeobox protein 2) as a key regulator in hepatic stellate ...

Jacob Elordi is riveting as a prisoner of war and love in Justin Kurzel's war epic miniseries 'The Narrow Road to the Deep ...

Lehigh Valley Health Network is making a major addition to its services, the health network, which is now part of ...

A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a ...

Step inside Asst. Prof. Sam Light’s lab to learn how scientists are mapping the incredible network of microbes living inside ...

Approximately 80 percent of patients with bladder cancer showed a reduction in tumor size, with no reported side effects ...

Today, if we are the lawabiding kind, we often have to wait at signals even if there’s no traffic flow from the other side ...

Global urinalysis market will reach $5,348.8 million by 2031, growing by 6.6% annually over 2021-2031, driven by the growing geriatric population, the prevalence of age-related diseases, the growing ...

TD Cowen increased its price target on Gilead Sciences (NASDAQ:GILD) shares to $100 from the previous $95, while maintaining a Buy rating on the stock. The biotech giant, currently trading near its 52 ...

Oppenheimer reiterated its Outperform rating and $115.00 price target for Gilead Sciences (NASDAQ:GILD) stock, following a strong fourth-quarter performance that surpassed consensus estimates. Gilead ...